Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report

Timothy S. Blackwell, Andrew M. Tager, Zea Borok, Bethany B. Moore, David A. Schwartz, Kevin J. Anstrom, Ziv Bar-Joseph, Peter Bitterman, Michael R. Blackburn, William Bradford, Kevin K. Brown, Harold A. Chapman, Harold R. Collard, Gregory P. Cosgrove, Robin Deterding, Ramona Doyle, Kevin R. Flaherty, Christine Kim Garcia, James S. Hagood, Craig A. Henke & 28 others Erica Herzog, Cory M. Hogaboam, Jeffrey C. Horowitz, Talmadge E. King, James E. Loyd, William E. Lawson, Clay B. Marsh, Paul W. Noble, Imre Noth, Dean Sheppard, Julie Olsson, Luis A. Ortiz, Thomas G. O'Riordan, Tim D. Oury, Ganesh Raghu, Jesse Roman, Patricia J. Sime, Thomas H. Sisson, Daniel Tschumperlin, Shelia M. Violette, Timothy E. Weaver, Rebecca G. Wells, Eric S. White, Naftali Kaminski, Fernando J. Martinez, Thomas A. Wynn, Victor J. Thannickal, Jerry P. Eu

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be approximately 3 years from the time of diagnosis, underscoring the lack of effective medical therapies for this disease. In the United States alone, approximately 40,000 patients die of this disease annually. In November 2012, the NHLBI held a workshop aimed at coordinating research efforts and accelerating the development of IPF therapies. Basic, translational, and clinical researchers gathered with representatives from the NHLBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Administration to review the current state of IPF research and identify priority areas, opportunities for collaborations, and directions for future research. The workshop was organized into groups that were tasked with assessing and making recommendations to promote progress in one of the following six critical areas of research: (1) biology of alveolar epithelial injury and aberrant repair; (2) role of extracellular matrix; (3) preclinical modeling; (4) role of inflammation and immunity; (5) genetic, epigenetic, and environmental determinants; (6) translation of discoveries into diagnostics and therapeutics. The workshop recommendations provide a basis for directing future research and strategic planning by scientific, professional, and patient communities and the NHLBI.

Original languageEnglish (US)
Pages (from-to)214-222
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume189
Issue number2
DOIs
StatePublished - Jan 15 2014

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Idiopathic Pulmonary Fibrosis
Education
Research
Patient Advocacy
United States Food and Drug Administration
Epigenomics
Extracellular Matrix
Immunity
Therapeutics
Research Personnel
Inflammation
Survival
Wounds and Injuries
Pharmaceutical Preparations
Direction compound

Keywords

  • Alveolar epithelial cells
  • Extracellular matrix
  • Idiopathic pulmonary fibrosis
  • Inflammation
  • Interstitial lung disease

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Blackwell, T. S., Tager, A. M., Borok, Z., Moore, B. B., Schwartz, D. A., Anstrom, K. J., ... Eu, J. P. (2014). Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report. American Journal of Respiratory and Critical Care Medicine, 189(2), 214-222. https://doi.org/10.1164/rccm.201306-1141WS

Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report. / Blackwell, Timothy S.; Tager, Andrew M.; Borok, Zea; Moore, Bethany B.; Schwartz, David A.; Anstrom, Kevin J.; Bar-Joseph, Ziv; Bitterman, Peter; Blackburn, Michael R.; Bradford, William; Brown, Kevin K.; Chapman, Harold A.; Collard, Harold R.; Cosgrove, Gregory P.; Deterding, Robin; Doyle, Ramona; Flaherty, Kevin R.; Garcia, Christine Kim; Hagood, James S.; Henke, Craig A.; Herzog, Erica; Hogaboam, Cory M.; Horowitz, Jeffrey C.; King, Talmadge E.; Loyd, James E.; Lawson, William E.; Marsh, Clay B.; Noble, Paul W.; Noth, Imre; Sheppard, Dean; Olsson, Julie; Ortiz, Luis A.; O'Riordan, Thomas G.; Oury, Tim D.; Raghu, Ganesh; Roman, Jesse; Sime, Patricia J.; Sisson, Thomas H.; Tschumperlin, Daniel; Violette, Shelia M.; Weaver, Timothy E.; Wells, Rebecca G.; White, Eric S.; Kaminski, Naftali; Martinez, Fernando J.; Wynn, Thomas A.; Thannickal, Victor J.; Eu, Jerry P.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 189, No. 2, 15.01.2014, p. 214-222.

Research output: Contribution to journalArticle

Blackwell, TS, Tager, AM, Borok, Z, Moore, BB, Schwartz, DA, Anstrom, KJ, Bar-Joseph, Z, Bitterman, P, Blackburn, MR, Bradford, W, Brown, KK, Chapman, HA, Collard, HR, Cosgrove, GP, Deterding, R, Doyle, R, Flaherty, KR, Garcia, CK, Hagood, JS, Henke, CA, Herzog, E, Hogaboam, CM, Horowitz, JC, King, TE, Loyd, JE, Lawson, WE, Marsh, CB, Noble, PW, Noth, I, Sheppard, D, Olsson, J, Ortiz, LA, O'Riordan, TG, Oury, TD, Raghu, G, Roman, J, Sime, PJ, Sisson, TH, Tschumperlin, D, Violette, SM, Weaver, TE, Wells, RG, White, ES, Kaminski, N, Martinez, FJ, Wynn, TA, Thannickal, VJ & Eu, JP 2014, 'Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report', American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 2, pp. 214-222. https://doi.org/10.1164/rccm.201306-1141WS
Blackwell, Timothy S. ; Tager, Andrew M. ; Borok, Zea ; Moore, Bethany B. ; Schwartz, David A. ; Anstrom, Kevin J. ; Bar-Joseph, Ziv ; Bitterman, Peter ; Blackburn, Michael R. ; Bradford, William ; Brown, Kevin K. ; Chapman, Harold A. ; Collard, Harold R. ; Cosgrove, Gregory P. ; Deterding, Robin ; Doyle, Ramona ; Flaherty, Kevin R. ; Garcia, Christine Kim ; Hagood, James S. ; Henke, Craig A. ; Herzog, Erica ; Hogaboam, Cory M. ; Horowitz, Jeffrey C. ; King, Talmadge E. ; Loyd, James E. ; Lawson, William E. ; Marsh, Clay B. ; Noble, Paul W. ; Noth, Imre ; Sheppard, Dean ; Olsson, Julie ; Ortiz, Luis A. ; O'Riordan, Thomas G. ; Oury, Tim D. ; Raghu, Ganesh ; Roman, Jesse ; Sime, Patricia J. ; Sisson, Thomas H. ; Tschumperlin, Daniel ; Violette, Shelia M. ; Weaver, Timothy E. ; Wells, Rebecca G. ; White, Eric S. ; Kaminski, Naftali ; Martinez, Fernando J. ; Wynn, Thomas A. ; Thannickal, Victor J. ; Eu, Jerry P. / Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report. In: American Journal of Respiratory and Critical Care Medicine. 2014 ; Vol. 189, No. 2. pp. 214-222.
@article{85b9f9562f794b898e9a43d0780bd1bb,
title = "Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report",
abstract = "The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be approximately 3 years from the time of diagnosis, underscoring the lack of effective medical therapies for this disease. In the United States alone, approximately 40,000 patients die of this disease annually. In November 2012, the NHLBI held a workshop aimed at coordinating research efforts and accelerating the development of IPF therapies. Basic, translational, and clinical researchers gathered with representatives from the NHLBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Administration to review the current state of IPF research and identify priority areas, opportunities for collaborations, and directions for future research. The workshop was organized into groups that were tasked with assessing and making recommendations to promote progress in one of the following six critical areas of research: (1) biology of alveolar epithelial injury and aberrant repair; (2) role of extracellular matrix; (3) preclinical modeling; (4) role of inflammation and immunity; (5) genetic, epigenetic, and environmental determinants; (6) translation of discoveries into diagnostics and therapeutics. The workshop recommendations provide a basis for directing future research and strategic planning by scientific, professional, and patient communities and the NHLBI.",
keywords = "Alveolar epithelial cells, Extracellular matrix, Idiopathic pulmonary fibrosis, Inflammation, Interstitial lung disease",
author = "Blackwell, {Timothy S.} and Tager, {Andrew M.} and Zea Borok and Moore, {Bethany B.} and Schwartz, {David A.} and Anstrom, {Kevin J.} and Ziv Bar-Joseph and Peter Bitterman and Blackburn, {Michael R.} and William Bradford and Brown, {Kevin K.} and Chapman, {Harold A.} and Collard, {Harold R.} and Cosgrove, {Gregory P.} and Robin Deterding and Ramona Doyle and Flaherty, {Kevin R.} and Garcia, {Christine Kim} and Hagood, {James S.} and Henke, {Craig A.} and Erica Herzog and Hogaboam, {Cory M.} and Horowitz, {Jeffrey C.} and King, {Talmadge E.} and Loyd, {James E.} and Lawson, {William E.} and Marsh, {Clay B.} and Noble, {Paul W.} and Imre Noth and Dean Sheppard and Julie Olsson and Ortiz, {Luis A.} and O'Riordan, {Thomas G.} and Oury, {Tim D.} and Ganesh Raghu and Jesse Roman and Sime, {Patricia J.} and Sisson, {Thomas H.} and Daniel Tschumperlin and Violette, {Shelia M.} and Weaver, {Timothy E.} and Wells, {Rebecca G.} and White, {Eric S.} and Naftali Kaminski and Martinez, {Fernando J.} and Wynn, {Thomas A.} and Thannickal, {Victor J.} and Eu, {Jerry P.}",
year = "2014",
month = "1",
day = "15",
doi = "10.1164/rccm.201306-1141WS",
language = "English (US)",
volume = "189",
pages = "214--222",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Future directions in idiopathic pulmonary fibrosis research an NHLBI workshop report

AU - Blackwell, Timothy S.

AU - Tager, Andrew M.

AU - Borok, Zea

AU - Moore, Bethany B.

AU - Schwartz, David A.

AU - Anstrom, Kevin J.

AU - Bar-Joseph, Ziv

AU - Bitterman, Peter

AU - Blackburn, Michael R.

AU - Bradford, William

AU - Brown, Kevin K.

AU - Chapman, Harold A.

AU - Collard, Harold R.

AU - Cosgrove, Gregory P.

AU - Deterding, Robin

AU - Doyle, Ramona

AU - Flaherty, Kevin R.

AU - Garcia, Christine Kim

AU - Hagood, James S.

AU - Henke, Craig A.

AU - Herzog, Erica

AU - Hogaboam, Cory M.

AU - Horowitz, Jeffrey C.

AU - King, Talmadge E.

AU - Loyd, James E.

AU - Lawson, William E.

AU - Marsh, Clay B.

AU - Noble, Paul W.

AU - Noth, Imre

AU - Sheppard, Dean

AU - Olsson, Julie

AU - Ortiz, Luis A.

AU - O'Riordan, Thomas G.

AU - Oury, Tim D.

AU - Raghu, Ganesh

AU - Roman, Jesse

AU - Sime, Patricia J.

AU - Sisson, Thomas H.

AU - Tschumperlin, Daniel

AU - Violette, Shelia M.

AU - Weaver, Timothy E.

AU - Wells, Rebecca G.

AU - White, Eric S.

AU - Kaminski, Naftali

AU - Martinez, Fernando J.

AU - Wynn, Thomas A.

AU - Thannickal, Victor J.

AU - Eu, Jerry P.

PY - 2014/1/15

Y1 - 2014/1/15

N2 - The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be approximately 3 years from the time of diagnosis, underscoring the lack of effective medical therapies for this disease. In the United States alone, approximately 40,000 patients die of this disease annually. In November 2012, the NHLBI held a workshop aimed at coordinating research efforts and accelerating the development of IPF therapies. Basic, translational, and clinical researchers gathered with representatives from the NHLBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Administration to review the current state of IPF research and identify priority areas, opportunities for collaborations, and directions for future research. The workshop was organized into groups that were tasked with assessing and making recommendations to promote progress in one of the following six critical areas of research: (1) biology of alveolar epithelial injury and aberrant repair; (2) role of extracellular matrix; (3) preclinical modeling; (4) role of inflammation and immunity; (5) genetic, epigenetic, and environmental determinants; (6) translation of discoveries into diagnostics and therapeutics. The workshop recommendations provide a basis for directing future research and strategic planning by scientific, professional, and patient communities and the NHLBI.

AB - The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be approximately 3 years from the time of diagnosis, underscoring the lack of effective medical therapies for this disease. In the United States alone, approximately 40,000 patients die of this disease annually. In November 2012, the NHLBI held a workshop aimed at coordinating research efforts and accelerating the development of IPF therapies. Basic, translational, and clinical researchers gathered with representatives from the NHLBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Administration to review the current state of IPF research and identify priority areas, opportunities for collaborations, and directions for future research. The workshop was organized into groups that were tasked with assessing and making recommendations to promote progress in one of the following six critical areas of research: (1) biology of alveolar epithelial injury and aberrant repair; (2) role of extracellular matrix; (3) preclinical modeling; (4) role of inflammation and immunity; (5) genetic, epigenetic, and environmental determinants; (6) translation of discoveries into diagnostics and therapeutics. The workshop recommendations provide a basis for directing future research and strategic planning by scientific, professional, and patient communities and the NHLBI.

KW - Alveolar epithelial cells

KW - Extracellular matrix

KW - Idiopathic pulmonary fibrosis

KW - Inflammation

KW - Interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=84892643019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892643019&partnerID=8YFLogxK

U2 - 10.1164/rccm.201306-1141WS

DO - 10.1164/rccm.201306-1141WS

M3 - Article

VL - 189

SP - 214

EP - 222

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -